AstraZeneca’s Fasenra once again falls short in COPDnews2025-09-17T11:09:23+00:00September 17th, 2025|Endpoints News|
Roivant tees up dermatomyositis drug filing on heels of Phase 3 successnews2025-09-17T11:00:40+00:00September 17th, 2025|Endpoints News|
#EADV25: Sanofi claims Phase 2a success in chronic skin conditionnews2025-09-17T05:00:02+00:00September 17th, 2025|Endpoints News|
#EASD25: Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo’s oral Wegovynews2025-09-16T22:01:48+00:00September 16th, 2025|Endpoints News|
CSL spends $117M to support development of VarmX’s blood clotting drugnews2025-09-16T10:42:02+00:00September 16th, 2025|Endpoints News|
GHO Capital buys Scientist.com, provider of a drug development marketplacenews2025-09-16T10:00:46+00:00September 16th, 2025|Endpoints News|
Genmab ends work on ADC from $1.8B acquisition of ProfoundBionews2025-09-15T23:28:14+00:00September 15th, 2025|Endpoints News|
Covid-19 vaccine makers sidelined ahead of upcoming ACIP meeting, sources saynews2025-09-15T21:22:10+00:00September 15th, 2025|Endpoints News|
aTyr Pharma’s stock plummets after Phase 3 flop in inflammatory lung diseasenews2025-09-15T15:11:26+00:00September 15th, 2025|Endpoints News|
Lilly’s UK Gateway Labs plans uncertain in new blow to region’s biopharma industrynews2025-09-12T15:19:34+00:00September 12th, 2025|Endpoints News|
